DSIP
DSIP

Price range: £14.99 through £24.99

Add to basket This product has multiple variants. The options may be chosen on the product page

DSIP

Price range: £14.99 through £24.99

  • UK Stock
  • Secure Payments
  • Discreet UK Delivery

DSIP (delta sleep-inducing peptide) is a synthetic nine-amino-acid research peptide studied in experimental sleep and neurobiology settings.

COMPLETE YOUR KIT

Bacteriostatic Water - 3ml
Bacteriostatic Water - 3ml

In stock

£3.99
GHK-Cu - 50mg
GHK-Cu - 50mg

In stock

£19.99
1 Vial
£14.99
1 Vial
£13.49 Save 10%
3 Vials
£12.74 Save 15%
5 Vials
£11.99 Save 20%

For in vitro laboratory research only.
Not for human or veterinary use. Not for diagnosis, treatment, cure, or prevention of any disease. No dosage, administration, or injection guidance is provided.

DSIP (delta sleep-inducing peptide) is a synthetic nine-amino-acid research peptide studied in experimental sleep and neurobiology settings. Its name reflects early findings, but published evidence does not establish it as a reliable sleep treatment.

Research material only This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.

Compound overview

Compound nameDSIP
Full nameDelta sleep-inducing peptide
Compound classLinear research peptide
Peptide length9 amino acids
Reference sequenceWAGGDASGE
Research focusSleep physiology and peptide biology

Research context

DSIP was described as a candidate sleep-associated peptide in early experimental work. Investigations have examined sleep structure and neurophysiological responses, but the biological mechanism remains unsettled. A later review questioned whether the exact peptide has been conclusively shown to occur naturally and noted the absence of an identified specific receptor.

Human studies are small and inconsistent. An early crossover study in six healthy volunteers reported sleep-related changes, whereas a double-blind study in 16 people with chronic insomnia found weak objective effects, no change in subjective sleep quality and no clear therapeutic benefit. These results do not justify assuming that DSIP improves sleep in people. See the Research tab for the linked publications.

Batch documentation

Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the compound, vial size and batch identifier to the corresponding report before relying on any result.

Supply and laboratory handling

  • Supplied in the vial size selected above.
  • Provided as a lyophilised research material.
  • Keep the vial sealed and protected from moisture, heat and direct light.
  • Use suitable laboratory controls and independently verify identity and concentration for the intended experimental model.

Frequently asked questions

What is DSIP?

DSIP is delta sleep-inducing peptide, a nine-amino-acid sequence used in experimental sleep and peptide research.

Does its name mean it reliably induces sleep?

No. The name comes from early research. Human findings are limited and mixed, and a controlled insomnia study did not find a meaningful overall therapeutic benefit.

Is its biological mechanism established?

No. The precise mechanism and natural occurrence of the exact peptide remain debated in the scientific literature.

Which vial size will I receive?

The supplied quantity is determined by the variation selected above. This description applies across available vial sizes.

Where can I find batch testing?

Check the product testing information for a published report matching the selected variation and batch. Published research is separate from batch-specific analytical documentation.

How should laboratory storage be determined?

Keep the material sealed and protected from moisture, heat and light. Follow batch documentation and the requirements of the validated laboratory protocol; solution stability depends on the experimental conditions.

Information reviewed 28 September 2026. Reference: Kovalzon and Strekalova, 2006.

Size

5mg, 10mg

Batch-specific analytical documentation

Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.

  • Result available: a published report is available for the marked variation.
  • Test pending: a sample has been submitted, but no completed result is being claimed.
  • No indicator: no product-specific result is currently displayed for that variation.

Check the identifiers

Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.

Browse published lab results →

Storage and stability

Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.

Form Suggested storage Important note
Sealed lyophilised material Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling.
Reconstituted solution Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed.

No universal shelf-life is claimed

Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.

Published research

DSIP has been examined in small human sleep studies and broader experimental work. The publications below show why the peptide name should not be interpreted as a proven sleep effect or clinical indication.

  1. Schneider-Helmert D et al. (1981). Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. International Journal of Clinical Pharmacology, Therapy and Toxicology 19(8):341–345.

    A double-blind crossover experiment in six healthy volunteers reported changes in sleep measures relative to placebo. The sample was too small to establish a reliable effect across populations or research conditions.

    PubMed record: PMID 6895513

  2. Bes F et al. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology 26(4):193–197.

    Sixteen people with chronic insomnia were studied in a double-blind matched-pairs design. Some objective measures shifted, but effects were weak, subjective sleep quality did not improve and the authors concluded that short-term DSIP was unlikely to provide major therapeutic benefit.

    PubMed record: PMID 1299794

  3. Kovalzon VM and Strekalova TV (2006). Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry 97(2):303–309.

    This critical review assessed conflicting sleep findings and questioned whether the exact DSIP sequence has been conclusively identified as a naturally occurring mammalian peptide. It also highlighted the lack of a demonstrated specific receptor mechanism.

    DOI: 10.1111/j.1471-4159.2006.03693.x · Journal article

Literature is not batch evidence Published studies do not establish the identity, purity, content or suitability of any supplied batch. DSIP is not established as a sleep treatment. Research use only; not for human or veterinary use.

References reviewed 28 September 2026.